Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Rea

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Leukemia|September 17, 2024
Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registryEkaterina Chelysheva, Jane Apperley, Anna Turkina, et al.
Leukemia|February 22, 2024
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registryEkaterina Chelysheva, Jane Apperley, Anna Turkina, et al.
Haematologica|May 20, 2017
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM studyDelphine Rea, Guylaine Henry, Zena Khaznadar, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Leukemia Research|May 21, 2025
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMCHyacinthe Johnson-Ansah, Aude Charbonnier, Gabriel Etienne, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
Blood|December 10, 2016
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI studyDelphine Rea, Franck E Nicolini, Michel Tulliez, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Leukemia|September 17, 2024
Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registryEkaterina Chelysheva, Jane Apperley, Anna Turkina, et al.
Leukemia|February 22, 2024
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registryEkaterina Chelysheva, Jane Apperley, Anna Turkina, et al.
Haematologica|May 20, 2017
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM studyDelphine Rea, Guylaine Henry, Zena Khaznadar, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2017
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysisAndreas Hochhaus, Franҫois-Xavier Mahon, Philipp le Coutre, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Leukemia Research|May 21, 2025
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMCHyacinthe Johnson-Ansah, Aude Charbonnier, Gabriel Etienne, et al.
Journal of Cancer Research and Clinical Oncology|April 2, 2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysisFrancis J Giles, Delphine Rea, Gianantonio Rosti, et al.
Blood|December 10, 2016
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI studyDelphine Rea, Franck E Nicolini, Michel Tulliez, et al.
Pageof 11